➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
Merck
Baxter
Medtronic

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,286,004

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,286,004
Title:Targeting-enhanced anticancer nanoparticles and preparation methods of same
Abstract: Targeting-enhanced anticancer nanoparticles and preparation methods for the nanoparticles are provided. In particular, this invention provides targeting-enhanced anticancer nanoparticles comprising non-covalently bound anticancer drugs, serum albumins as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties. The targeting-enhanced anticancer nanoparticles described in the present invention are characterized by non-covalently bound constituents: anticancer drugs, serum albumin as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties, thus preventing common toxic side effects, enhancing the structural stability of nanoparticles, and enhancing tumor targeting by treatment with electromagnetic waves due to the activity of porphyrin, without structural and functional changes. Taken together, the present invention provides a chemotherapeutic method that maximizes drug delivery/tumor targeting and is expected to be a successful therapy for both early-stage and late-stage cancer.
Inventor(s): Kim; Hyeon Jin (Wanju-gun, KR), Hong; Seong Tshool (Jeonju-si, KR), Chung; Hea Jong (Jeonju-si, KR), Joo; Min Kyu (Jeonju-si, KR), Cho; Hea Guk (Gwangju, KR), Hong; Jinny (Jeonju-si, KR)
Assignee: JINIS CO., LTD. (Wanju-gun, KR)
Application Number:15/481,950
Patent Claims:see list of patent claims

Details for Patent 10,286,004

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial JINIS CO., LTD. (Wanju-gun, KR) 2033-05-02 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Medtronic
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.